Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Egg phosphatidylcholine (egg-PC) is a natural phospholipid-form choline supplement derived from egg yolk. It is primarily used in clinical research to address nutritional choline deficiency in preterm infants, who have high requirements for choline to support rapid brain development and membrane synthesis. Unlike inorganic choline salts, egg-PC provides choline in a lipid-bound form, which is integrated into the synthesis of phosphatidylcholine and sphingomyelin in cell membranes. It also serves as a precursor for the neurotransmitter acetylcholine and the methyl donor betaine, and it facilitates the plasma transport of polyunsaturated fatty acids (PUFA). The compound has been studied by Universitätsklinikum Tübingen in pharmacokinetic trials (e.g., DRKS00020502) to evaluate its efficacy in increasing plasma choline levels in neonates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on egg phosphatidylcholine.